Mimicking Borderline Resectable Population in Solitary Hepatocellular Carcinoma of BCLC Stage A
Background Early recurrence (≤ 6 months) after curative resection of hepatocellular carcinoma (HCC) carries markedly worse prognosis than late recurrence. While borderline resectable (BR1/BR2) HCC is defined anatomically, a biologically high-risk subgroup with BR-like features may exist within resectable (R) disease; we developed and validated a preoperative score to identify such patients within BCLC Stage A primary HCC. Methods We analyzed a single-center discovery cohort of 473 patients with solitary BCLC Stage A primary HCC (2001–2021) and a later validation cohort of 63 patients (2022–2025). An additive 2-factor score (0–2) combined tumor size (≥ 60 mm) and PIVKA-II (≥ 50 mAU/mL); ROC/Youden-index analysis in the same cohort yielded closely similar thresholds. Bootstrap resampling that re-derived cutoffs within each replicate showed a less optimistic, more variable AUC than the fixed-cutoff model. Results Early recurrence occurred in 44/473 (9.3%) discovery patients and carried worse 5-year overall survival than late or no recurrence (38.1% vs. 78.4% vs. 94.6%; p < 0.001). Tumor size ≥ 60 mm (OR 3.94) and PIVKA-II ≥ 50 mAU/mL (OR 2.27) were independent predictors. The score stratified early-recurrence risk in discovery (score 0/1/2: 4.4%/7.7%/27.9%; AUC 0.694, optimism-corrected 0.662–0.692) and validation cohorts (5.6%/12.2%/50.0%; AUC 0.664, 95% CI 0.421–0.870), and was independently associated with distant recurrence after adjustment for early-recurrence status (adjusted OR 3.01 per point, p < 0.001). Conclusions A simple 2-factor score combining tumor size and PIVKA-II identifies, within solitary BCLC Stage A HCC, a high-risk subgroup whose recurrence mimics borderline resectable (BR1) disease. Preoperative (neoadjuvant) systemic therapy in this high-risk group warrants prospective evaluation.
Authors
- Yuki Ushimaru (ORCID: https://orcid.org/0000-0003-1096-0980)
- Yoshihiro Sakano (ORCID: https://orcid.org/0000-0002-7633-6657)
- Yuki Yokota (ORCID: https://orcid.org/0000-0001-9332-5717)
- Shogo Kobayashi (ORCID: https://orcid.org/0000-0002-8828-1067)
- Yoshinori Kagawa (ORCID: https://orcid.org/0000-0001-6876-4507)
- Hiroshi Miyata (ORCID: https://orcid.org/0000-0002-1062-9158)
- Yoshitomo Yanagimoto (ORCID: https://orcid.org/0000-0001-6369-6023)
- Kazuyoshi Yamamoto (ORCID: https://orcid.org/0000-0002-7645-2412)
- Takashi Kanemura (ORCID: https://orcid.org/0000-0001-9125-6228)
- Hisateru Komatsu
- Yasunari Fukuda (ORCID: https://orcid.org/0000-0002-5550-7736)
- Toshinori Sueda (ORCID: https://orcid.org/0000-0002-7459-7458)
- Masatoshi Kitakaze (ORCID: https://orcid.org/0000-0003-0497-7639)
- Norihiro Matsuura (ORCID: https://orcid.org/0000-0001-8956-4600)
- Tsuyoshi Hata (ORCID: https://orcid.org/0000-0001-6616-9069)
- Kunihito Gotoh (ORCID: https://orcid.org/0000-0002-6890-6293)
- Kei Adachi (ORCID: https://orcid.org/0009-0008-4283-5424)
- Kota Momose
- Kaoru Fujikawa
- Yuta Kobayashi
- Kei Yamamoto
Institutions
- Osaka International Cancer Institute (JP)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-18
- DOI
- https://doi.org/10.21203/rs.3.rs-11544562/v1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- preprint